Amerise Biosciences Ltd (531681) — FY26 Annual Report | 1 September 2026
Amerise Biosciences Limited reported a net profit of ₹1.61 lakhs for FY2025-26, up from ₹0.57 lakhs in FY2024-25, driven by higher other income and controlled expenses, though revenue remained negligible. The company appointed Albert Hines as Whole-Time Director and CFO effective February 2, 2026, on nil remuneration. No dividend was recommended due to accumulated losses. The AGM is scheduled for September 24, 2026, where shareholders will vote on the financial statements and director appointments. The board emphasized minimal operational activity and ongoing search for business opportunities.
About Amerise Biosciences Ltd (531681)
Services · Miscellaneous · Listed on BSE
📡 Get AI alerts when 531681 files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track 531681 — Free💡 Ask AI about this filing
📊 More 531681 filings
No other filings yet.
🔥 Also filed on 1 September 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts for your stocks — summarized by AI daily
Set up your AI Radar — pick stocks, get daily email summaries of new filings.
Set up AI Radar — FreeFree account · 2 AI queries/day
© 2026 StockFin.ai — AI-powered Indian stock research
About · Privacy Policy · Terms of Service · Pricing
Today's Announcements · Screener · Insights · AI Chat
Data provided by CMOTS Internet Technologies Pvt Ltd